209 related articles for article (PubMed ID: 38175353)
1. The Global Landscape on the Access to Cancer Medicines for Breast Cancer: The ONCOLLEGE Experience.
Lengyel CG; Habeeb BS; Altuna SC; Trapani D; Khan SZ; Hussain S
Cancer Treat Res; 2023; 188():353-368. PubMed ID: 38175353
[TBL] [Abstract][Full Text] [Related]
2. The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2-positive breast cancer: The ONCOLLEGE-001 survey.
Trapani D; Lengyel CG; Habeeb BS; Altuna SC; Petrillo A; El Bairi K; Hussain S; Mazher SA; Elfaham EM; Curigliano G; Khan SZ
J Cancer Policy; 2021 Jun; 28():100285. PubMed ID: 35559914
[TBL] [Abstract][Full Text] [Related]
3. Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars.
Jackisch C; Lammers P; Jacobs I
Breast; 2017 Apr; 32():199-216. PubMed ID: 28236776
[TBL] [Abstract][Full Text] [Related]
4. The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.
Blackwell K; Gligorov J; Jacobs I; Twelves C
Clin Breast Cancer; 2018 Apr; 18(2):95-113. PubMed ID: 29525430
[TBL] [Abstract][Full Text] [Related]
5. Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
Zardavas D; Fouad TM; Piccart M
Breast; 2015 Nov; 24 Suppl 2():S143-8. PubMed ID: 26255196
[TBL] [Abstract][Full Text] [Related]
6. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies.
Whalen J
Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
8. Breast Cancer: Reimbursement Policies and Adoption of New Therapeutic Agents by National Health Systems.
Trapani D; Curigliano G; Eniu A
Breast Care (Basel); 2019 Dec; 14(6):373-381. PubMed ID: 31933583
[TBL] [Abstract][Full Text] [Related]
9. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.
Paplomata E; Nahta R
Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review.
Müller V; Bartsch R; Lin NU; Montemurro F; Pegram MD; Tolaney SM
Cancer Treat Rev; 2023 Apr; 115():102527. PubMed ID: 36893691
[TBL] [Abstract][Full Text] [Related]
12. Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States.
Sussell JA; Press DJ; Hansen SA; Kim E; Du Toit Y; Fung A
Adv Ther; 2023 Sep; 40(9):3857-3874. PubMed ID: 37358705
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI.
Pituskin E; Haykowsky M; Mackey JR; Thompson RB; Ezekowitz J; Koshman S; Oudit G; Chow K; Pagano JJ; Paterson I
BMC Cancer; 2011 Jul; 11():318. PubMed ID: 21794114
[TBL] [Abstract][Full Text] [Related]
14. Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China.
Li J; Wang S; Wang Y; Wang X; Wang H; Feng J; Zhang Q; Sun T; Ouyang Q; Yin Y; Liu Y; Geng C; Yan M; Jiang Z
Oncologist; 2017 Nov; 22(11):1333-1338. PubMed ID: 28798274
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in the United States.
Sussell J; Singh Jhuti G; Antao V; Herrera-Restrepo O; Wehler E; Bilir SP
Am J Clin Oncol; 2021 Jul; 44(7):340-349. PubMed ID: 34151896
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
[TBL] [Abstract][Full Text] [Related]
17. Availability and affordability of anticancer medicines in Iran based on WHO/HAI standard survey methods.
Varmaghani M; Elyasi S; Mojahedian MM; Ghavami V; Borhani B; Javan-Noughabi J; Sarafraz S
Support Care Cancer; 2022 Dec; 31(1):89. PubMed ID: 36574075
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy de-escalation using an
Pérez-García JM; Gebhart G; Ruiz Borrego M; Stradella A; Bermejo B; Schmid P; Marmé F; Escrivá-de-Romani S; Calvo L; Ribelles N; Martinez N; Albacar C; Prat A; Dalenc F; Kerrou K; Colleoni M; Afonso N; Di Cosimo S; Sampayo-Cordero M; Malfettone A; Cortés J; Llombart-Cussac A;
Lancet Oncol; 2021 Jun; 22(6):858-871. PubMed ID: 34019819
[TBL] [Abstract][Full Text] [Related]
19. Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.
Niikura N; Shimomura A; Fukatsu Y; Sawaki M; Ogiya R; Yasojima H; Fujisawa T; Yamamoto M; Tsuneizumi M; Kitani A; Watanabe J; Matsui A; Takahashi Y; Takashima S; Shien T; Tamura K; Saji S; Masuda N; Tokuda Y; Iwata H
Breast Cancer Res Treat; 2018 Jan; 167(1):81-87. PubMed ID: 28895005
[TBL] [Abstract][Full Text] [Related]
20. Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands.
Luyendijk M; Blommestein H; Uyl-de Groot C; Siesling S; Jager A
JAMA Netw Open; 2023 Feb; 6(2):e2256170. PubMed ID: 36795415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
